Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$73.63
+1.5%
$73.43
$55.02
$98.40
$3.50B1.25706,677 shs494,003 shs
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$105.55
-0.8%
$99.87
$43.89
$111.02
$6.61B0.7471,894 shs464,283 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$5.96
+1.5%
$6.68
$1.25
$10.53
$4.12B1.033.54 million shs2.69 million shs
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
$39.95
$38.88
$9.39
$39.99
$5.50B1.063.62 million shsN/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+1.54%-0.37%-3.03%-2.53%-9.00%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-0.79%+2.14%-1.16%+16.63%+79.63%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+1.53%-2.30%-26.42%+16.18%+107.67%
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
0.00%0.00%0.00%0.00%+4.75%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.3704 of 5 stars
4.50.00.04.52.24.20.6
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
0.5267 of 5 stars
2.32.00.00.02.10.80.6
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
0.0826 of 5 stars
1.01.00.00.01.61.70.6
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.92
Moderate Buy$122.0865.81% Upside
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.63
Moderate Buy$108.002.32% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.00
Hold$6.000.67% Upside
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
N/AN/AN/AN/A

Current Analyst Ratings

Latest ISEE, AXSM, BPMC, and IBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$106.00 ➝ $106.00
6/7/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$125.00 ➝ $125.00
6/6/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$190.00 ➝ $190.00
6/5/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$127.00 ➝ $130.00
5/14/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$140.00
5/8/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$109.00 ➝ $106.00
5/7/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $125.00
5/7/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$190.00
5/7/2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$108.00 ➝ $112.00
5/6/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
5/6/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$121.00 ➝ $168.00
(Data available from 6/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$270.60M12.92N/AN/A$4.04 per share18.23
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$249.38M26.50N/AN/A$2.15 per share49.09
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$620K6,648.00N/AN/A($0.88) per share-6.77
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
N/AN/AN/AN/A$4.43 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$239.24M-$6.38N/AN/AN/A-118.07%-87.17%-32.81%8/5/2024 (Estimated)
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$506.98M-$4.81N/AN/AN/A-102.15%-193.48%-42.98%8/7/2024 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$583.20M-$1.09N/AN/AN/A-198,994.05%N/A-114.89%8/13/2024 (Estimated)
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
-$185.21M-$1.76N/AN/AN/AN/A-57.00%-46.15%N/A

Latest ISEE, AXSM, BPMC, and IBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.16-$0.20-$0.04-$0.20$0.03 million$0.04 million
5/6/2024Q1 2024
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.20-$1.09+$0.11-$0.74$69.91 million$75.00 million
5/2/2024Q1 2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$1.64-$1.32+$0.32-$4.04$82.58 million$96.12 million
3/19/2024Q4 2023
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.18-$0.19-$0.01N/A$0.03 million$0.14 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.25
3.20
3.09
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
0.67
3.76
3.61
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
3.64
3.64
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
0.20
15.53
15.53

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
N/A

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.40%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
4.21%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
83.40%
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
2.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
54547.50 million36.86 millionOptionable
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
65562.62 million59.98 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
628691.57 million114.80 millionOptionable
IVERIC bio, Inc. stock logo
ISEE
IVERIC bio
163137.78 million134.06 millionOptionable

ISEE, AXSM, BPMC, and IBRX Headlines

Recent News About These Companies

Astellas Pharma Inc (ALPMY)
10 Best Isee Case Ipods
Apellis adds safety warning to eye therapy
Astellas Completes Acquisition of Iveric Bio
B.Riley Financial Sticks to Its Hold Rating for IVERIC bio (ISEE)
Iveric bio, Still A 5+% Opportunity
IVERIC Bio (NASDAQ: ISEE)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Axsome Therapeutics logo

Axsome Therapeutics

NASDAQ:AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Blueprint Medicines logo

Blueprint Medicines

NASDAQ:BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
ImmunityBio logo

ImmunityBio

NASDAQ:IBRX
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
IVERIC bio logo

IVERIC bio

NASDAQ:ISEE
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.